Alys Pharmaceuticals

Alys Pharmaceuticals

生物技术研究

An Innovation Leader in Immuno-Dermatology

关于我们

Launched in February 2024, Alys Pharmaceuticals is an innovation leader in immuno-dermatology, co-founded by Medixci and world-leading dermatology and scientific experts. Originating from the aggregation of six asset-centric Medixci compannies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications. With a vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet medical need, Alys aspires to redefine the landscape of dermatological treatments. Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics, and has a number of strategic collaborations with leading research institutions.

网站
alyspharma.com
所属行业
生物技术研究
规模
11-50 人
类型
私人持股
创立
2024

Alys Pharmaceuticals员工

动态

相似主页

融资

Alys Pharmaceuticals 共 1 轮

上一轮

种子轮

US$100,000,000.00

投资者

Medicxi
Crunchbase 上查看更多信息